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The objective of the study was to investigate the predictive value of various clinical, biochemical, and histopathological parameters,
with special emphasis on the expression of the retinoblastoma protein (pRB), on the radiation response in bladder cancer. In order to
obtain a truly objective response measure, patients receiving preoperative radiotherapy followed by cystectomy were studied.
Pretreatment tumour samples and clinical data from 108 consecutive patients were collected. End points were complete response
(CR) to radiotherapy, relapse-free survival time and overall survival time. Expression of pRB was assessed by immunohistochemical
staining as present or absent. Complete response to radiotherapy was obtained in 42 of 106 evaluable patients (40%). Predictive for
CR to radiotherapy, in univariate analysis, was transurethral resection (as opposed to biopsy), B-haemoglobin, no upper urinary
retention, and loss of pRB staining. Loss of pRB staining was the strongest independent predictor of radiation response in multivariate
logistic regression analysis and absence of upper urinary retention was the only other significant factor. Loss of pRB was the only
parameter showing statistically significant, independent association with relapse-free survival, whereas B-haemoglobin was also
independently associated with overall survival. Loss of pRB expression seems to indicate a phenotype displaying enhanced
radiosensivity and may be of benefit by denoting patients who would selectively benefit from a treatment schedule containing
radiotherapy.
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The role of radiotherapy in the treatment of muscle-invasive
bladder cancer is changing. Although the superiority of radical
cystectomy over curatively intended radiotherapy has never been
tested in randomised trials, retrospective analyses seem to favour
the first (Shelley et al, 2001). For the vast majority of patients
cystectomy is, consequently, the treatment of choice in most
countries. Definite radiotherapy is offered to patients medically
unfit for major surgery, patients refusing cystectomy, and patients
with locally advanced disease (T4 or N1 disease) in most centres.
Lasting local control can, however, be achieved by radiotherapy in
a significant proportion of patients.
Encouraged by the obvious benefits of bladder conservation in
terms of quality of life, multimodality bladder conserving
therapies, combining organ sparing surgery with chemo-and
radiotherapy, have been designed and promising results have
been published (Dunst et al, 1994; Kaufman et al, 2000; Kim and
Steinberg, 2000; Rodel et al, 2002). Radiotherapy, therefore, seems
to be re-entering the treatment of bladder cancer. However, organ-
sparing treatment is an option only in select patients, reflecting the
fact that much is to be gained by improving patient selection or
individualising treatment of the specific patient. Our tools for this
task are limited as only TNM stage, grade, and performance status
are widely recognised as decisive for the choice of treatment.
Tumour heterogeneity in terms of radiosensivity in bladder
cancer is remarkable (Barnetson et al, 1999), and only to a limited
extent correlated to conventional clinical and histopathological
parameters. The rapidly increasing insight into the molecular
factors responsible for malignant transformation, cell cycle
control, and response to therapy offers new, potentially prognostic,
information on individual tumours. The retinoblastoma protein
(pRB) is both a tumour suppressor and a pivotal player in the cells
protection against genotoxic stress mainly by inducing arrest at the
cell cycle checkpoints to allow DNA repair (Bartek and Lukas,
2001). Loss of expression of the RB gene both contributes to the
oncogenesis per se and thwarts the ability of the tumour cell to
respond to the toxic effects of radiotherapy. pRB-deficient cells
have accordingly been found to be hypersensitive to DNA damage-
induced apoptosis (Knudsen et al, 2000; Wang et al, 2001). In
bladder cancer, pRB-negative tumours have been shown to have
higher proliferative indices (Lipponen and Liukkonen, 1995), a
quality that might well influence both radiosensitivity and clinical
behaviour. Loss of pRB expression is found in a significant
proportion of transitional cell bladder cancers, which supports its
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ycandidacy as a clinically relevant molecular marker of increased
radioresponsiveness in this disease.
MATERIALS AND METHODS
Patients
A total of 108 consecutive patients with invasive transitional cell
bladder cancer (T1–T4a) receiving preoperative radiotherapy
followed by radical cystectomy at the Departments of Oncology
and Urology, Aarhus University Hospital, in the period from 1980
to 1992 were included in the study. Clinical data of relevance were
extracted from patient files. Paraffin-embedded pretreatment
tumour biopsies and embedded sections of the excised bladder
after radiotherapy were available from all patients. Tumour stage
was determined by cystoscopy, biopsy or resection of the tumour
and bimanual palpation under general anaesthesia in accordance
with the UICC/AJCC recommendations (1997). Metastatic disease
was excluded by chest X-ray, bone scan in the case of bone pain,
ultrasonography of the upper abdomen in the case of abnormal
liver biochemistry and, in the majority of the patients (100 pts.), by
a CT scan of the pelvis. Transurethral resection of the bladder
tumour (TUR-B) was performed prior to radiotherapy in 60
patients (56%), leaving macroscopic tumour tissue in the bladder
wall in 44 (41%), no macroscopic tumour but residual tumour
demonstrable in biopsies from the resected area in 14 (13%), and
neither visible nor histopathologically demonstrable residual
tumour in two patients (2%). In the remaining 48 patients, only
biopsing of the bladder tumours was performed. A total of 106 of
the 108 patients thus had verified residual tumour at the initiation
of radiotherapy. Clinical data, pretreatment laboratory results, and
pathology reports were retrieved from archives. Presence or
absence of upper urinary retention was documented in 103
patients (95%) by intravenous pyelography and/or renography.
Revision of the histological specimens was performed (by MA
and NM) ensuring a uniform classification of pre-and post-
treatment tumour stage and grade according to Bergkvist (1965).
Presence or absence of CIS was recorded only in patients where
systematic biopsing of bladder mucosa had been performed. It was
noted whether patients were diagnosed with muscle-invasive
disease on initial presentation or had experienced disease
progression from a ‘pre-muscle-invasive stage’ (Ta, Tis, or T1)
over a period of time (43 months), and by that went through a
period of surveillance allowing ‘early’ treatment of the muscle-
invasive tumour.
Radiotherapy
As treatment policies changed slightly over time, all patients
included were treated according to one of three schemes: 40Gy in
20 fractions (47 pt.),. 42Gy in 20 fractions (50 pt.), or 46Gy in 23
fractions (12 pt.); in all cases with five fractions per week. All but
one patient received the planned radiation schedule; the last
patient received 38 of planned 40Gy, the last fraction being
omitted for reasons not recorded. Radiotherapy was planned based
on a CT scan in 100 patients, whereas the remaining eight were
planned after conventional X-ray simulation. All treatments were
given with a three-field box technique (anterior and two opposing
lateral fields), using 8MV photons for the anterior field and 16MV
for the lateral fields. Treatment volumes averaged 2210cm
3 (1260–
4788; sd¼632).
Response to radiotherapy was evaluated from the excised
bladders as either complete response (CR)–absence of residual
malignant cells in the cystectomy specimen upon thorough
histopathological examination–, or incomplete response (IR)–
presence of residual malignancy in cystectomy specimen. No
attempt was made on evaluating partial responses/downstaging.
Treatment of relapse
Of the 58 patients experiencing a relapse of bladder cancer after
cystectomy, only three received potentially life-prolonging treat-
ment with systemic chemotherapy. A total of 14 patients received
palliative radiotherapy (mainly on metastatic sites) and three
patients had palliative surgical resections. In all, 39 patients
received only supportive treatment for their relapse.
Immunohistochemical staining
The 4cm sections of archival, formalin-fixed, paraffin-embedded
tumour tissue were placed on silane-coated slides, deparaffinised
in xylene, and rehydrated through graded alcohols. Endogenous
peroxidase was quenched by rinsing with 0.5% hydrogen peroxide
in absolute ethanol for 20min followed by rinsing in Tris/PBS (pH
7.6) and water. Heat-induced antigen retrieval was performed
using a T-EG buffer (Tris 10mMþEGTA 0.5mM; pH 9.0) and
microwave heating for 3 5min followed by cooling for 20min in
the buffer. After rinsing twice in Tris/PBS, slides were incubated
overnight at 41C with primary antibody (monoclonal mouse anti-
human retinoblastoma gene product Rb1 (formerly designated
1F8), DAKO) diluted 1:200 in Antibody Diluent (DAKO).
Following another two rinses in Tris/PBS, bound primary antibody
was visualised by incubation with EnVisiontþ/HRP Mouse
(DAKO) for 30min, three rinses in Tris/PBS and 5min in liquid
DABþ (DAKO). Sections were counterstained with Mayer’s
haematoxylin and mounted in dibutyl phthalate xylene medium
(DPX, BDH Laboratory Supplies, WNR International, Poole,
England).
Staining of nuclei of fibroblasts, endothelial cells, or other
normal tissue components of the surrounding stroma served as
individual positive controls of the staining reaction in each slide.
Negative controls were performed for each batch by omitting the
primary antibody. Tumours were classified as pRB negative when
no staining of tumour cell nuclei was seen in sections showing
positive staining of adjacent stromal cell nuclei. Cytoplasmic
staining was disregarded. Six of the pRB-positive tumours
contained areas of negatively staining tumour cells (mixed staining
pattern). These were classified as pRB positive.
Statistics
Categorical data were compared in univariate analysis using the w
2
test or Fischer’s exact test where appropriate, and censored data
were compared using log-rank test. Continuous variables were
dichotomised using median value (age) or ‘normal limits’ (B-
haemoglobin (above 8.0mmoll
 1 in males, above 7.0mmoll
 1 in
females) and S-creatinine (below 110mmoll
 1)) as cutoff points.
Multivariate analyses were performed using logistic regression
analysis (response to radiotherapy) and Cox proportional hazards
models (disease-free-and overall survival). All variables were
tested in univariate analyses (w
2/Fischer’s and log-rank test), and
variables showing significant correlations with end points or
variables indicated as prognostic factors in the literature were
entered into the multivariate analyses. All statistical analyses were
performed using the SPSS 10.0 statistical package (SPSS Inc., IL,
USA).
RESULTS
Complete response to preoperative radiotherapy was found in 42
of 106 patients (40%) with residual tumour after TUR-B. A strong
correlation between radiation response and relapse (P o 0.001),
relapse-free survival time (Po0.0001), and overall survival time
(P¼0.0001) was found (Table 1). Table 2 shows the various
parameters examined, their distribution in the group of complete
responders vs incomplete responders to radiotherapy, and the
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radiotherapy and age, sex, grade of atypia, histological type,
pattern of growth, multifocality, lymphovascular invasion, coex-
istence of CIS, diagnose of a pre-muscle-invasive stage, or
radiation dose was found. T stage was not significantly associated
with the radiation response, where T3a tumours exhibited the
highest proportion of complete responders (14 of 29¼48%).
Serum creatinine within normal limits and no macroscopic tumour
left after TUR-B was more frequent among complete responders
albeit not reaching statistical significance (P¼0.14 and 0.24).
Predictive for CR to radiotherapy in univariate analysis was
resection at TUR-B (as opposed to biopsy) (P¼0.02), B-
haemoglobin within normal limits (P¼0.03), no upper urinary
retention on IVP or renography (P¼0.001), and loss of pRB
staining (P¼0.004).
No correlation between pRB status and tumour grade or stage
(or any other of the examined parameters) was seen. Significant
correlations were noted between upper urinary retention and T-
stage (P¼0.03) and S-creatinine above normal limits (P¼0.001)
and between T stage and grade of atypia (P¼0.008) (data not
shown).
In multivariate logistic regression analysis, only absence of pRB
immunostaining (P¼0.004) and absence of upper urinary
retention (P¼0.032) were statistically significant independent
predictors of CR to radiotherapy (Table 3).
When tested individually for association with relapse-free
survival time (using Kaplan–Meier/log-rank test, Figure 1), only
absence of pRB staining showed statistical significance as a
prognostic marker (P¼0.033). T stage was not significantly
associated with survival but showed the most marked separation
between survival of groups when divided in to two: ‘T3b and
higher’ and ‘T3a and lower’, where a P-value of 0.22 was seen.
Grade was significantly associated with disease-free survival after 1
year (P¼0.018), but not with further follow-up (P¼0.299)
(Figure 3). Separation, although not statistically significant, was
also seen for biopsy vs resection at TUR-B (P¼0.07) and B-
haemoglobin within or below normal limits (P¼0.17). When
entering the above factors in a Cox regression analysis (Table 4),
only pRB had statistically significant independent prognostic
significance (P¼0.030). Changing the end point to overall survival
time made B-haemoglobin a significant prognostic marker along
with pRB (Figure 2 and Table 5) in univariate analysis (P¼0.003)
as well as in multivariate Cox regression (P¼0.002) and the
statistical significance of pRB status was strengthened in both
(P¼0.021 and 0.009, respectively).
DISCUSSION
Apart from T staging, classical clinical and histopathological
parameters have shown limited value as predictors for the
radiocurability of muscle-invasive bladder cancer. The present
study supports this view, as neither grade of anaplasia nor
histological pattern of growth and differentiation, lymphovascular
invasion, multifocality, simultaneous presence of CIS, or the
registration of a pre-muscle-invasive stage correlated significantly
with the tumour response to radiotherapy. T stage has previously
been demonstrated to be predictive for the outcome in bladder
cancer subjected to radical radiotherapy (Sengelov and von der
Maase, 1999). However, when cohorts receiving preoperative
radiotherapy have been examined, correlations have been less
consistent (Pollack et al, 1997b; Rotterud et al, 2001). In this
context, it is important to realise that the supposed benefit from
preoperative radiotherapy lies in an effect on micrometastatic
spread at the time of surgery and not in the eradication of the
primary tumour. Complete response to radiotherapy is thus an
indicator of radiosensitivity, but not a prerequisite for the desired
end point. Undoubtedly, the low precision of clinical staging
documented in many surgical series (Pagano et al, 1991; Cheng
et al, 2000) contributes greatly to the lack of predictive value of T
staging. The recognition of upper urinary retention as a prognostic
marker for radiosensitivity per se probably reflects the ability of
this examination to reveal an advanced local tumour stage as
reflected by the observed significant association between T stage
and upper urinary retention, rather than the effect of impaired
renal function.
The effects of subnormal haemoglobin concentration could be
dual. Low haemoglobin increases the risk of tumour hypoxia,
which has been demonstrated to influence the outcome of
radiotherapy in bladder cancer (Gospodarowicz et al, 1989;
Hoskin et al, 1999). Anaemia, on the other hand, also often
accompanies advanced cancer disease as well as other wasting
diseases and may, consequently, be a marker hereof and as such
associated with decreased overall survival. In the present study, B-
haemoglobin below normal limits was significantly correlated to IR
in univariate analysis, suggesting an effect of hypoxia. The
statistical significance, however, disappeared in the multivariate
analysis. B-haemoglobin below normal limits was independently
associated with decreased overall survival but not with disease-free
survival in the Cox analysis, implicating a more general effect.
Grade of atypia of the tumour has been shown to carry
independent prognostic information concerning survival in some
studies of radical radiotherapy in bladder cancer (Gospodarowicz
et al, 1989; Greven et al, 1990), while others have failed to find such
an association (Fossa et al, 1993; Fung et al, 1991). The present
study did not show statistically significant correlation between
grade and CR to radiotherapy. It was, however, noted (Figure 3)
that grade 4 tumours relapsed earlier, although not more
frequently,- than tumours of lower grades (grade 3), resulting in
a significant difference in relapse-free survival after 1 year of
follow-up. After 2 years, the difference was reduced to a
statistically insignificant level (P¼0.089) and survival curves
merged beyond 4 years of follow-up.
The extent of resection obtained at TUR-B reflects both the size
and extent of the tumour present and the treatment policy of the
surgeon. No systematic information regarding the size of the
tumours was available, so a possible association with this
parameter could not be tested. The surgical procedure preceding
radiotherapy (incomplete resection vs biopsy) correlated signifi-
cantly with the response to treatment, as would be expected. The
association, however, was not independent, as it was not
statistically significant in the multivariate analysis. Macroscopic
Table 1 Correlations between complete response (CR) to radiotherapy and outcome in 106 evaluable
patients (two patients not evaluable for response to radiotherapy because of microscopically radical TUR-B;
n.r.: not reached)
Relapse (%) Median relapse-free
survival in months (s.e.)
Median overall survival
in months (s.e.)
CR (n¼42) 13 (31) n.r. 104 (74)
IR (n¼64) 42 (68) 17 (2) 15 (3)
P-value 0.001 o0.0001 0.0001
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Parameter
Number of
patients
%C Rt o
radiotherapy
%I Rt o
radiotherapy P-value
Age 56 39 61
Above median 50 40 60 1.00
Below median
Sex 89 39 61
Male 17 41 59 1.00
Female
Grade 1 0 100
II 83 40 60
III 22 41 59 0.72
IV
Stage 4 25 75
T1 27 41 59
T2 29 48 52
T3a 34 38 62
T3b 12 25 75 0.67
T4a
IVP or renography 74 51 49
Normal 27 15 85 0.001
Upper urinary retention 5
Not available
S-creatinine 85 44 56
Within normal limits 21 24 76 0.14
Above normal limits
B-haemoglobin 78 46 54
Within normal limits 28 21 79 0.03
Below normal limits
CIS 36 42 58
Yes 38 37 63 0.81
No 32
Not available
Pre-muscle-invasive stage 38 37 63
Yes 68 41 59 0.69
No
Radicality of TURB 48 27 73
Biopsy 58 50 50 0.02
Resection
Macroscopic complete TUR-B 14 57 43
Macroscopic incomplete TUR-B 44 48 52 0.24
Histology 88 41 59
Pure TCC 18 33 67 0.61
TCC with squamous/adenocarc. diff.
Lymphovascular invasion 25 40 60
No lymphovascular invasion 81 39 61 1.00
Papillary (partly or completely) 53 43 57
Solid (completely) 53 36 64 0.55
Multifocality 14 36 64
Yes 92 40 60 1.00
No
Radiotherapy 12 42 58
46Gy 48 33 67
42Gy 46 41 59 0.28
40Gy
pRB 66 29 71
Positive 40 58 42 0.004
Negative
Two patients not evaluable for response to radiotherapy because of microscopically radical TUR-B; TCC¼transitiocellular
carcinoma, TUR-B¼Transurethral resection of bladder tumour, IVP¼intravenous pyelography, CIS¼presence of
carcinoma in situ in biopsies from bladder mucosa).
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surprisingly, not significantly associated with CR or survival. This
could in part be ascribable to the low number of patients in whom
complete resection was obtained, but could also be an indicator
that the combined clinical and histopathological diagnose of
complete resection is not a good reflection of the actual situation.
The strongest and most consistent independent predictor of
both CR to radiotherapy and survival was found to be the
expression of pRB. Loss of expression of pRB was observed in 37%
of tumours (40 of 108), a number corresponding well with the
findings of other studies (Geradts et al, 1994; Cordon-Cardo et al,
1997; Pollack et al, 1997a, b; Cote et al, 1998; Moonen et al, 2001).
Thus, loss of this cell cycle control factor is seen in a clinically
relevant proportion of bladder tumours adding to its relevance as a
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Figure 1 Kaplan–Meier plot of relapse-free survival of patients with
pRB-negative (—) and pRB-positive (- -) tumours. (þ) marks censoring
events.
Table 3 Results of multivariate logistic regression analysis in 101
evaluable patients
Parameter P OR 95% CI
Negative pRB staining 0.004 4.07 1.57–10.53
Upper urinary retention 0.032 0.25 0.07–0.88
Biopsy only at TUR-B 0.094 0.46 0.18–1.15
B-haemoglobin below normal 0.212 0.45 0.13–1.58
Two patients not evaluable for response to radiotherapy because of microscopically
radical TUR-B, five patients excluded because of lack of information on result of IVP
or renography. Dependent variable: CR to radiotherapy. OR¼overall response;
CI¼confidense interval.
Table 4 Results of Cox regression analysis including all 108 patients.
Dependent variable: relapse-free survival
Parameter P OR 95% CI
Negative pRB staining 0.030 0.51 0.28–0.94
B-haemoglobin below normal 0.170 1.52 0.84–2.77
Biopsy only at TUR-B 0.144 1.48 0.87–2.52
Grade 4 0.314 1.39 0.73–2.65
T stage3B 0.591 1.16 0.68–1.96
Table 5 Results of Cox regression analysis including all 108 patients.
Dependent variable: overall survival
Parameter P OR 95% CI
Negative pRB staining 0.009 0.52 0.32–0.85
B-haemoglobin below normal 0.002 2.13 1.31–3.44
Grade 4 0.111 1.54 0.91–2.61
Biopsy only at TUR-B 0.294 1.27 0.81–1.99
T stageX3B 0.868 1.04 0.66–1.64
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Figure 2 Kaplan–Meier plot of overall survival of patients with pRB-
negative (—) and pRB-positive (- -) tumours. (þ) marks censoring events.
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43
Figure 3 Kaplan–Meier plot of relapse-free survival of patients with
grade 2þ3 (—) and grade 4 (- -) tumours. (þ) marks censoring events. P
values calculated with 1, 2, 4, and 16 years of follow-up.
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bladder cancers, applying radically intended radiotherapy, have
investigated the effects of pRB expression on the outcome
(Jahnson et al, 1995; Moonen et al, 2001). The study by Jahnson
et al (1995) included 154 patients and showed more complete
tumour responses (defined as absence of tumour at cystoscopy
with biopsies at 6–7 months) and increased cancer–specific
survival among pRB-negative patients, although without reaching
statistical significance. The recent study by Moonen et al (2001)
evaluated 83 patients with a relatively high proportion of early-
stage tumours (39% T1, 45% T2, 16%T3, and no T4) treated with a
wide range of total doses (46–72Gy) and doses per fraction (1.8–
3Gy, mean 2.4Gy). This study also found loss of pRB staining to
be associated with increased local control (70% vs 39% free of local
recurrence at 3 years), but again without reaching statistical
significance in either uni-or multivariate analysis. Besides our
investigation, another study has employed the results of pre-
operative radiotherapy for evaluating the radioresponsiveness of
bladder cancer in relation to pRB. The study by Pollack et al
(1997a) found pRB status to be the only pretreatment prognostic
factor that was independently associated with complete radiation
response, but could only demonstrate a survival benefit in a
subgroup analysis for stage T3B patients. In striking contrast to
these findings, when pRB status has been studied in a series of
purely surgically managed bladder cancer, loss of pRB expression
has consistently been related to aggressive disease course and
decreased survival (Cordon-Cardo et al, 1992; Logothetis et al,
1992; Cordon-Cardo et al, 1997; Cote et al, 1998; Grossman et al,
1998).
In conclusion, the results of the present investigation demon-
strate pRB immunoreactivity as an independent predictive factor
for radiosensitivity and an independent prognostic factor for
survival in muscle-invasive bladder cancer. The available literature
seems to indicate that loss of RB protein expression in bladder
cancer confers a more aggressive phenotype resulting in decreased
survival when applying an exclusively surgical strategy but also an
increased radiosensitivity resulting in at least equal results in
radically irradiated series and in a survival benefit when modalities
are combined. It follows that treatment of pRB-negative bladder
cancers might selectively benefit from radiotherapy either alone or
as preoperative radiotherapy followed by cystectomy, or perhaps
as part of the newer bladder sparing regimens with aggressive local
surgery and combined radiotherapy and chemotherapy.
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